Table I.

Prostate cancer patients with or without HER2 amplification.

Patient ID	Age	Situation	PSA	Pathologic grade	Gleason score	Green signal	Red signal	Green/red
P-709	55	L	5.1	2	4	271	116	2.31
P-436	82	R	8.1	3b	5	410	134	3.05
P-1139	56	L	8.2	2	4	201	83	2.42
P-100	65	L	9.2	3a		355	130	2.73
P-326	61	L	9.3	4b	6	296	90	3.28
P-435	82	R	6.1	3a	5	168	75	2.24
P-1101	67	R	195	4b	7	401	134	2.99
P-564	66	L	10.9	3a	6	201	68	2.95
P-62	69	L	32.8	3a	5	278	116	2.39
P-27	83	L	9.3	3a	5	180	71	2.53
P-63	61	R	14.8	3a	5	214	95	2.25
P-425	82	L	16.2	3a	5	220	75	2.93
P-599	75	R	74.3	4b	7	224	88	2.54
P-13	83	R	16.4	4b	6	485	181	2.67
P-68	70	L	156.2	4b	7	182	73	2.49
P-80	70	R	9.2	4	6	465	193	2.41
P-69	66	L	19.2	4	7	459	186	2.46
P-137	78	R	20.8	4	6	150	68	2.22
P-162	75	L	33.1	4	6	421	166	2.53
P-691	65	L	4.95	2	4	444	256	1.73
P-993	61	L	69.8	4b	8	212	165	1.28
P-1084	82	L	45.7	4a	7	–	–	–
P-806	78	L	6.1	4b	7	229	112	2.04
P-856	80	L	78.3	4a	6	240	123	1.95
P-27	83	L	8.1	3a	5	221	110	2.00
P-150	68	R	8.9	4b	6	–	120	–
P-439	82	L	6.1	3a	5	160	79	2.02
P-174	57	R	5.5	2	4	112	60	1.80
P-12	71	L	18.6	3c	5	478	233	2.05
P-37	77	L	140.1	4	6	110	59	1.86
P-83	58	L	7.3	4	5	165	86	1.91
P-164	74	R	4.4	4	5	596	281	2.12

HER2 amplification was considered when the green/red ratio was >2.2. HER2, human epidermal growth factor receptor 2; PSA, prostate-specific antigen; L, left; R, right.